Reduction of Serum Ferritin after Deferasirox Treatment in Thalassemic Children
Abstract
Background
Thalassemia is a prevalent genetic disorder in South Asia, including Bangladesh, where transfusion-dependent patients are at risk of iron overload. Deferasirox, an oral iron chelator, is widely used to manage iron burden.
Objective
This study evaluates the efficacy of deferasirox in thalassemic children.
Methods
This pretest-posttest quasi-experimental study was conducted at the Bangladesh Shishu (Children) Hospital and Institute, Dhaka, involving 50 transfusion-dependent thalassemic children aged 2–18 years. Serum ferritin was measured before and after six months of deferasirox therapy. Statistical analysis included paired t-tests, with p-values <0.05 considered significant.
Results
The mean serum ferritin level decreased significantly from 2462±1169 ng/mL to 1874±1002 ng/mL (p<0.001), with a mean reduction of 588±367 ng/mL and a percentage reduction of 24.60±13.00%.
Conclusion
Deferasirox effectively reduces serum ferritin levels in transfusion-dependent thalassemic children. These findings contribute to evidence-based strategies for managing iron overload in resource-limited settings.
J Rang Med Col. March 2025; Vol.10, No.1: 82-86
Keywords:
Thalassemia
Deferasirox
Serum ferritin
Iron overload
Pediatric hematology
Bangladesh